Comparing INmune Bio (NASDAQ:INMB) & Compugen (NASDAQ:CGEN)

INmune Bio (NASDAQ:INMB) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

3.2% of INmune Bio shares are held by institutional investors. Comparatively, 47.4% of Compugen shares are held by institutional investors. 67.7% of INmune Bio shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares INmune Bio and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
INmune Bio N/A -32.17% -31.05%
Compugen N/A -46.10% -35.88%

Volatility and Risk

INmune Bio has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for INmune Bio and Compugen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INmune Bio 0 0 3 0 3.00
Compugen 0 0 7 0 3.00

INmune Bio currently has a consensus price target of $11.33, suggesting a potential upside of 123.98%. Compugen has a consensus price target of $18.57, suggesting a potential upside of 17.62%. Given INmune Bio’s higher possible upside, equities research analysts plainly believe INmune Bio is more favorable than Compugen.

Earnings and Valuation

This table compares INmune Bio and Compugen’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
INmune Bio N/A N/A -$7.68 million ($0.75) -6.75
Compugen $17.80 million 60.69 -$27.34 million ($0.43) -36.72

INmune Bio has higher earnings, but lower revenue than Compugen. Compugen is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Summary

INmune Bio beats Compugen on 6 of the 11 factors compared between the two stocks.

About INmune Bio

INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.